Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumors New candidate APVO455 targets Nectin-4+ cancers, joins ...

We are at an inflection point that is driving a renaissance in antibody-drug conjugate (ADC) development. As successes in the clinic have led to more U.S. Food & Drug Administration (FDA) approvals, ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

Breakthrough Trispecific Antibody Shows Strong Early Efficacy: JNJ-5322 demonstrated an 86.1% overall response rate (ORR) at the recommended Phase II dose in heavily pretreated multiple myeloma ...

An overview of the articles in this Focus issue on therapeutic antibodies. Over the past 10 years, the market for monoclonal antibodies has grown exponentially. This focus issue brings together ...

Antibodies are secreted immunoglobulin molecules produced mainly by plasma cells. The antigen-binding site of the antibody has a unique structure that allows it to bind antigen in a highly ...

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...

If you’ve been exposed to the herpes virus, it can take anywhere from 2 to 10 days for symptoms to appear and for the virus to be detected on a test. Learn more.

This repository contains the antibody-antigen test cases, with unbound and bound structures, for Docking Benchmark 5.5. This dataset is a major update of Docking Benchmark 5.0, which was released in ...

Antibodies are important for protection against malaria. For optimal protective activity, it is thought that antibodies need to have high affinity. A longitudinal study conducted in Uganda followed ...

1 Introduction Antibody affinity maturation (AM) is a dynamic evolutionary process orchestrated primarily within germinal centers (GCs) (1 – 3), where antibody-producing B cells undergo rounds of ...